HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Androgen depletion up-regulates cadherin-11 expression in prostate cancer.

Abstract
Men with castration-resistant prostate cancer (PCa) frequently develop metastasis in bone. The reason for this association is unclear. We have previously shown that cadherin-11 (also known as OB-cadherin), a homophilic cell adhesion molecule that mediates osteoblast adhesion, plays a role in the metastasis of PCa to bone. Here, we report that androgen-deprivation therapy up-regulates cadherin-11 expression in PCa. In human PCa specimens, immunohistochemical staining showed that 22/26 (85%) primary PCa tumours from men with castration-resistant PCa expressed cadherin-11. In contrast, only 7/50 (14%) androgen-dependent PCa tumours expressed cadherin-11. In the MDA-PCa-2b xenograft animal model, cadherin-11 was expressed in the recurrent tumours following castration. In the PCa cell lines, there is an inverse correlation between expression of cadherin-11 and androgen receptor (AR), and cadherin-11 is expressed in very low levels or not expressed in AR-positive cell lines, including LNCaP, C4-2B4 and VCaP cells. We showed that AR likely regulates cadherin-11 expression in PCa through an indirect mechanism. Although re-expression of AR in the AR-negative PC3 cells led to the inhibition of cadherin-11 expression, depletion of androgen from the culture medium or down-regulation of AR by RNA interference in the C4-2B4 cells or VCaP cells only produced a modest increase of cadherin-11 expression. Promoter analysis indicated that cadherin-11 promoter does not contain a typical AR-binding element, and AR elicits a modest inhibition of cadherin-11 promoter activity, suggesting that AR does not regulate cadherin-11 expression directly. Together, these results suggest that androgen deprivation up-regulates cadherin-11 expression in prostate cancer, and this may contribute to the metastasis of PCa to bone. Our study suggests that therapeutic strategies that block cadherin-11 expression or function may be considered when applying androgen-ablation therapy.
AuthorsYu-Chen Lee, Chien-Jui Cheng, Miao Huang, Mehmet A Bilen, Xiangcang Ye, Nora M Navone, Khoi Chu, Hsin-Hsin Kao, Li-Yuan Yu-Lee, Zhengxin Wang, Sue-Hwa Lin
JournalThe Journal of pathology (J Pathol) Vol. 221 Issue 1 Pg. 68-76 (May 2010) ISSN: 1096-9896 [Electronic] England
PMID20191612 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright (c) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Chemical References
  • Androgens
  • Cadherins
  • Neoplasm Proteins
  • Receptors, Androgen
  • osteoblast cadherin
Topics
  • Androgens (deficiency)
  • Animals
  • Cadherins (biosynthesis, genetics)
  • Gene Expression Regulation, Enzymologic (physiology)
  • Humans
  • Male
  • Mice
  • Mice, Nude
  • Neoplasm Proteins (biosynthesis, genetics)
  • Neoplasm Recurrence, Local (metabolism, surgery)
  • Orchiectomy
  • Promoter Regions, Genetic
  • Prostatic Neoplasms (genetics, metabolism)
  • Receptors, Androgen (metabolism)
  • Tumor Cells, Cultured
  • Up-Regulation
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: